ABSTRACT
RÉSUMÉ CONTEXTE: Le virus de l'immunodéficience humaine (VIH) est une cause majeure de mortalité infantile et la mortalité infantile et la morbidité; sans traitement d'environ 50% d'entre eux succombent au VIH / SIDA avant l'âge de deux ans. OBJECTIF: évaluer l'utilité des manifestations cliniques de l'infection par le VIH comme un substitut à la numération des CD4 dans les naïfs de traitement antirétroviral des enfants infectés par le VIH. MÉTHODES: les enfants nouvellement diagnostiqués infectés par le VIH, naïfs de traitement antirétroviral pédiatrique assister à une unité de maladies infectieuses ont été inscrits. Les manifestations cliniques-tions, l'âge, le sexe, et de l'OMS au stade clinique de chaque patient ont été déterminées. numération des CD4 et CD4% ont été estimés à la présentation et la corrélation avec diverses manifesta-

INTRODUCTION
Human immunodeficiency virus (HIV) infection is a major cause of infant and childhood mortality and morbidity. An estimated 2.3 million children were reported to be living with HIV/AIDS as at the end of 2006; two million of these children were in sub-Saharan Africa. 1 The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) reported that only 40,000 of the more than 660,000 HIV positive children requiring antiretroviral therapy (ART) were receiving it in 2005 and without treatment about 50% of them will succumb to HIV/AIDS before the age of two years. 2 The absolute CD4+ lymphocyte count and percentage, and plasma viral load have been considered the most reliable markers of disease progression in HIV-infected patients [3] [4] and have been the basis for indicating ART as well as prophylaxis against opportunistic infections (OIs). However, these tests require resources and technical expertise, neither of which is routinely available in resource-poor settings such as Nigeria. Opportunistic infections in HIV-infected children are generally seen in the setting of severe depression of the CD4 count. 5 It is therefore reasonable to assume that concomitant manifestations of opportunistic infections may reflect a severe drop in CD4 count thereby making clinical manifestations (CMs) a possible surrogate for CD4 cell count. In an effort to scale-up ARV therapy in developing countries the WHO has recommended the use of Paediatric HIV clinical staging system in initiating antiretroviral therapy in children where CD4 count is unavailable. 2 For effective patient management in resource limited settings, there is the need to assess the usefulness of alternative markers such as the CMs. This study aimed to evaluate CMs as surrogate for CD4 count in HIV-infected children in Africa.
SUBJECTS, MATERIALS, AND METHODS Subjects
One hundred and twenty-six newly diagnosed HIV-infected and antiretroviral-naïve children attending the paediatric infectious diseases unit at the University of Maiduguri Teaching Hospital (UMTH), Maiduguri, north-east Nigeria, from July 2006 to June 2007 were enrolled. The UMTH serves as a tertiary referral centre for infectious diseases from the neighbouring states and from the Cameroon, Niger and Chad republics.
Their HIV status was confirmed by Western blot test after an initial reactive ELISA test (Orgenic, Israel). Polymerase chain reaction (PCR) for HIV-1 DNA was used to confirm HIV status in children less than 18 months.
Ethical approval was obtained from the ethical committee of UMTH. Written consent for participation in the study was obtained from children's parents/ caregivers at the time of enrolment. Following consent, further analysis of absolute CD4 count and CD% was done.
On enrolment, a fill-in protocol detailing biodata, clinical history and physical examination was conducted for each of the patient with special emphasis on clinical features of HIV. Information obtained was entered into a data sheet and analysed for correlation of CD4 count and CD% with various clinical features. Using the WHO paediatric HIV clinical staging system, 6 patients were allocated to stages 1, 2, 3 or 4.
Mode of Transmission
History of blood transfusion, use of non-sterilized body piercing instruments, traditional surgery, sexual exposure/abuse and maternal HIV status in order to establish the likely source of infection was also sought. In children in whom the aforementioned sources could not be determined are considered to be unknown.
Definition of Terms
Persistent generalized lymphadenopathy (PGL) was diagnosed as the presence of enlarged lymph nodes (one cm) in two or more sites, excluding other causes. Hepatomegaly was defined as liver size greater than two cm palpable below the costal margin at right midclavicular line and splenomegaly as spleen enlargement palpable per abdomen. 7 Clinical oral candidiasis was registered if pseudomembranous oral lesion was observed. 8 Persistent diarrhoea was diagnosed as diarrhoea lasting more than 14 days associated with weight loss.
Failure to thrive (FTT) was defined by weight of less than 80% of expected weight for age and height of less than 90% of expected height for age. 9 Tuberculosis was diagnosed on the basis of symptomatology, history of adult contact with open tuberculosis, radiology, Mantoux test, sputum or gastric lavage for acid-fast bacilli, lymph node biopsy, poor response to antibiotic therapy and response to antituberculous treatment. 10 Pneumocytis carinii pneumonia (PCP) was diagnosed on the basis of dyspnoea, fever and radiological evidence of bilateral diffuse alveolar infiltrates. 10 Lymphoid interstitial pneumonia (LIP) was diagnosed on the basis of chronic respiratory symptoms, hypoxia and radiology showing interstitial pulmonary infiltration that responded poorly to antibiotic therapy with at least two of the following: bilateral parotid swelling, generalized lymphadenopathy, digital clubbing or response to corticosteroids. 10 HIV nephropathy was determined by the presence of significant proteinuria with or without other deranged renal function tests and excluding other causes of renal dysfunction.
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Laboratory Evaluation
Dynal beads technique (Dynal Biotech, Oslo, Norway) for CD4 counting was used. This technique uses paramagnetic polymer beads coated with anti-CD4 monoclonal antibodies to capture and isolate the CD4 from the blood. Other investigations done were dictated by the clinical condition of the patients.
Data Analysis
Data was analyzed using SPSS statistical software version 10. Statistical analysis included one way ANOVA and paired t-test for comparison. A p-value of <0.05 was considered significant for all statistical comparisons. Average values are presented as mean ±SD.
RESULTS
Study Population
The study group consisted of 126 children aged four months to 14 years with a mean of 3.2 ± 2.7 years. Of the 126 children, 69 (54.8%) were male and 57 (45.2%) were female with a male to female ratio of 1.2:1.
Mode of Transmission
The predominant mode of transmission was mother-to-child transmission (MTCT) in 102 (81%) patients, sexual exposure in three (2.4%), through blood transfusion in two (1.6%) and unknown in 19 (15%).
Correlation between CD4 count and Clinical Manifestations
CD4 count was estimated in 121 patients and CD4 % in 96. The mean CD4 count and CD4% showed an inverse relationship with age, with children less than one year having the higher values and those over five year having lower values (Table 1) .Using the WHO paediatric clinical staging system, 22 (17.5%) patients were in stage 1, 31 (24.6%) in stage 2, 59 (46.8%) in stage 3 and 14 (11.1%) in stage 4. Twelve patients in stage 4 (86%) are less than 24 months of age. The CD4% in each of the stages is shown in Fig. 1 . The correlation between CD4% and clinical 'stage showed a decreasing trend with transition from stage 1 to 4, (r = 0.62, p = 0.002).
The common clinical presentations and variation of CD4% and CD4 count in each clinical presentation as shown in Table 2 . Absolute CD4 count was relatively high in patients with stage 1 disease (lymphadenopathy and hepatosplenomegaly), compared with low count in patients with FTT and oral thrush (stage 3).
DISCUSSION
Plasma HIV Type 1 (HIV-1) viral load, the number of CD4 cells and CD% are still the useful markers for predicting the clinical course and response to ART as well as starting prophylaxis for opportunistic infections in HIV-infected adults and children. 3, 4 However, the infrastructure of clinical laboratories located in many resource-constrained countries can't afford to perform these tests required for implementation of HIV therapy. 11 In this study, we have evaluated the clinical presentations of HIV infection as a surrogate for CD4 count/CD4% in determining the optimal time to initiate antiretroviral therapy in HIV-infected African children.
Mode of HIV Transmission
The predominant mode of transmission was MTCT in 102 (81%) patients in the present study. Several other reports [12] [13] [14] [15] showed that MTCT accounted for 80% or more of HIV transmission. Research findings provide a strong rationale for implementation of prevention of mother-to-child transmission (PMTCT) interventions in resource-poor countries, especially in Africa. [16] [17] 
Correlation between CD4 count and Clinical Manifestations
In this study, the CD4 count and CD4% were higher in infants with subsequent decline in children over five years of age. This finding is in consonance with that of HIV Pediatric Prognostic Markers Collaborative Study Group 18 and the Paediatric European Network for treatment of AIDS (PENTA) 19 that CD4 count/CD4% varied with age. Analysis of age-related clinical staging showed that, the younger children aged one year and below were all in the advanced and severe stages. This is in agreement with other studies from Nigeria [12] [13] [14] and from other developing countries. [20] [21] This severe manifestation of HIV infection in most developing countries may be responsible for the 45-50% of HIV infected children in Africa dying from the disease before their second birthday without treatment.
In this study we observed a decreasing trend in CD4% with transition from stage 1 to 4, with an overall modest correlation between paired CD4% and WHO paediatric HIV clinical stages in 126 HIV-infected African children. The result of our study supports the WHO recommendation for initiating antiretroviral therapy in children using clinical staging alone where viral load and CD4 count estimation are not available. The WHO recommends the initiation of antiretroviral drugs in children in stages 3 and 4 irrespective of the CD4 count, especially in younger children. 2 In conclusion, this study has provided additional information with regard to the use of clinical manifestations of HIV infection as a surrogate to CD4 count in initiating antiretroviral therapy in Africa children. It is also necessary to take into account the relationship of CD4 count with age. It is important, too, to remember that inter-current infection might artificially reduce the CD4 count and therefore, in the presence of infection, CD4% correlates better. Prevention of mother-to-child transmission is the most cost-effective antiretroviral programme and one of the most attractive interventions for prevention of HIV. It is hoped the result will help in scaling-up antiretroviral treatment to over 660,000 HIV-infected children who presently need care. 
